Literature DB >> 25280463

A new lexicon for polypharmacy: Implications for research, practice, and education.

Chris Gillette1, Leesa Prunty2, Janet Wolcott2, Kimberly Broedel-Zaugg2.   

Abstract

Previous research suggests that polypharmacy is a significant challenge for health care systems. However, polypharmacy has been defined in at least 24 distinct ways, which has understandably caused confusion among researchers, educators, and students in health care. Previous definitions of polypharmacy capture what could be both inappropriate therapy, i.e. too many medications, as well as evidence-based therapy that is appropriate. Previous research has tried to focus on the number of medications a patient is prescribed to define polypharmacy; however only focusing on the number of medications a patient is taking may be of limited value in determining whether that patient will experience an adverse event. This paper proposes a lexicon change for polypharmacy. It suggests that in future research, polypharmacy be defined as patients going to more than one pharmacy for their prescriptions. The authors also proffer a new term, 'extraordinary prescribing,' to define patients who are taking medications that are either grossly excessive or not beneficial for that patient. This definition is different than the current use of polypharmacy because the number of medications a patient is taking is irrelevant, especially if that patient has multiple chronic diseases. This paper is meant to start a dialog within the health services research community to inform future research that examines why inefficient prescribing may harm patients and the broader health care system.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Education; Pharmacy; Polypharmacy; Research

Mesh:

Year:  2014        PMID: 25280463     DOI: 10.1016/j.sapharm.2014.08.010

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  8 in total

Review 1.  Polypharmacy and potentially inappropriate medication use in geriatric oncology.

Authors:  Manvi Sharma; Kah Poh Loh; Ginah Nightingale; Supriya G Mohile; Holly M Holmes
Journal:  J Geriatr Oncol       Date:  2016-08-03       Impact factor: 3.599

Review 2.  Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review.

Authors:  Michele Fornaro; Domenico De Berardis; Ann Sarah Koshy; Giampaolo Perna; Alessandro Valchera; Davy Vancampfort; Brendon Stubbs
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-31       Impact factor: 2.570

3.  Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study.

Authors:  Julien Castioni; Pedro Marques-Vidal; Nazanin Abolhassani; Peter Vollenweider; Gérard Waeber
Journal:  BMC Health Serv Res       Date:  2017-12-21       Impact factor: 2.655

4.  Current and future perspectives on the management of polypharmacy.

Authors:  Mariam Molokhia; Azeem Majeed
Journal:  BMC Fam Pract       Date:  2017-06-06       Impact factor: 2.497

5.  The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea.

Authors:  Hae-Young Park; Ji-Won Park; Hong Ji Song; Hyun Soon Sohn; Jin-Won Kwon
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

Review 6.  Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts-Results of a Literature Review.

Authors:  Najwa Taghy; Linda Cambon; Jean-Marie Cohen; Claude Dussart
Journal:  Ther Clin Risk Manag       Date:  2020-02-11       Impact factor: 2.423

Review 7.  What is polypharmacy? A systematic review of definitions.

Authors:  Nashwa Masnoon; Sepehr Shakib; Lisa Kalisch-Ellett; Gillian E Caughey
Journal:  BMC Geriatr       Date:  2017-10-10       Impact factor: 4.070

8.  An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study.

Authors:  Naiqi Zhang; Jan Sundquist; Kristina Sundquist; Jianguang Ji
Journal:  Front Pharmacol       Date:  2020-03-18       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.